Amgen struck a deal to buy cancer drug maker Onyx Pharmaceuticals for about $10.4 billion, as it moves to restock its product pipeline in response to declining sales of its flagship anemia drugs. The acquisition—which ends a two-month …
A federal judge rejected Amgen Inc.'s effort to temporarily block a competitor from releasing a copycat version of one of its top-selling biologic drugs. The Thousand Oaks biotech company had accused Novartis subsidiary Sandoz of violating …
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Amgen, Inc. a score of 41. Our analysis is based on comparing Amgen, Inc. with the following peers – Pfizer Inc., Bristol-Myers Squibb …
SHREVEPORT, La., Nov. 3, 2004 (PRIMEZONE) -- Stock-Letter-Daily.Com (http://www.stock-letter-daily.com -- an affiliate site of StockPickReport, the web's only non-mainstream stock rating service), rates Microsoft, Yahoo!, Calpine, Amgen …
The Dow edged up early Friday after third-quarter US economic growth bested expectations, while the Nasdaq fell on disappointing earnings from Amazon and Amgen. US economic growth accelerated to a 2.9 ...
*Insider roster data is derived solely from the last 24 months of Form 3 & Form 4 SEC filings.